Trigeminal Rhizotomy Performed with Modern Image-guided Linac: Case Report

Bobby C. Baker¹, Thomas A. Sullivan¹

¹. Pacific Cancer Institute

Corresponding author: Bobby C. Baker, bb@cancermd.net

Disclosures can be found in Additional Information at the end of the article

Abstract

Introduction: There are substantive articles published within the last ten years describing the use of linear accelerator (Linac) based treatment of trigeminal neuralgia (TN). In this paper, we report a single case of a patient with classic TN successfully treated by radiosurgical rhizotomy using a modern image-guided linear accelerator with a high-definition multileaf collimator and an optically guided targeting system. The measurement of absolute dose prior to treatment greatly facilitated our confidence with radiosurgical lesioning.

Materials and Methods: This 54-year-old patient had a six-year history of lancinating pain involving the lower third of the right face which dramatically intensified in December of 2012, shortly after beginning Vincristine. A treatment plan was generated using a nine-field dynamic arc technique. A target volume was placed at 2-3 mm from the root entry zone measuring 6 x 3 x 5 mm. The PTV dose was prescribed to 60 Gy to the 80% isodose line. Initial verification of absolute dose using Gafchromic film resulted in an increase of the planned MU’s by 7.5%. Remeasurement improved the absolute dose to within ±2 % of the calculated dose.

Results: The patient was evaluated two weeks and three months following treatment. Her trigeminal pain was 80% resolved after two weeks and 100% at the three-month evaluation. She required none of her chronic pre-treatment medications and demonstrated no clinically detected sensory deficits.

Conclusions: Linear accelerator-based radiosurgery utilizing intrafraction motion management and image guidance offers an acceptable alternative for the radiation treatment of trigeminal neuralgia patients if absolute doses are measured prior to treatment.

Introduction

The Gamma Knife has historically been the "Gold-Standard" for the radiosurgical lesioning of trigeminal neuralgia (TN) [1-2]. By administering 60-90 Gy with a Co-60 source through a 4 mm aperture, the Gamma Knife has been shown to produce conformal isodose distributions and correspondingly excellent clinical results [5-7].

Many radiation oncology facilities are limited to linear accelerator-based radiation treatments and must resort to referring TN patients to the nearest Gamma Knife or CyberKnife facilities. The advent of image-guided linear accelerators with intrafraction motion management systems...
have created an opportunity to safely treat these patients with the same level of accuracy and precision as frame-based and dedicated radiosurgery systems. This offers radiation oncologists the opportunity to offer this type of treatment in community-based practices.

There are substantive articles published within the last ten years describing the use of linear accelerator (linac)-based treatment of TN [8-12]. The consensus indicates that radiosurgery treatment of TN with a linear accelerator offers comparable outcomes to frame-based Gamma Knife systems. Most of these linac techniques use a 4 to 5 mm fixed circular cone to collimate the dose.

Pacific Cancer Institute of Maui recently commissioned a Varian Truebeam STx linear accelerator with an HD120 MLCs and AlignRT, an optically guided targeting system (Varian Medical Systems, Palo Alto, CA). Our premise for treating TN patients was based on the assumption that the 2.5 mm multi-leaf collimator (MLC) might provide sufficient resolution for trigeminal nerve lesioning, if one were to utilize pretreatment absolute dose confirmation. In this paper, we report a single case of a patient with classic trigeminal neuralgia successfully treated by radiosurgical rhizotomy using a modern image-guided linear accelerator.

**Case Presentation**

This 54-year-old patient had a six-year history of lancinating pain involving the lower third of the right face, which dramatically intensified in December of 2012 shortly after beginning Vincristine. Despite maximum doses of amitriptyline, gabapentin, and narcotics, the patient was having no pain relief. Because the patient was actively receiving chemotherapy for an advanced nodular lymphoma, she was judged to be at high risk of a postoperative infection and a good candidate for microvascular decompression.

The trigeminal neuralgia patient was immobilized during computerized tomography (CT) simulation with a custom Accuform cushion and aquaplast mask with a built-in bite block. A CT was acquired with 1.25 mm slice thicknesses throughout the head. T1 and T2-weighted magnetic resonance imaging (MRI) images were reconstructed from volume acquisitions into 1 mm slices. These images were fused with the treatment planning CT dataset for identification of the trigeminal root entry zone (REZ). The planned target volume measured approximately 6 x 3 x 3 mm. Critical organs at risk (OAR), such as the brainstem, cochlea, ipsilateral Gasserian ganglion, and the 7th/8th nerve complex, were also delineated (Figure 1).
The Eclipse treatment planning computer, V11.0 (Varian Medical Systems, Palo Alto, CA), was used to calculate the isodose distribution using nine dynamic arcs strategically placed to minimize the dose to the OARs (Figure 2). Several of the arcs were repeated (reversed direction) to achieve the MU/degree within machine tolerances (≤ 60). VMAT (Volumetric Modulated Arc Therapy) was not used because the small beamlets produced by the MLC modulation were thought to add more uncertainty to the accuracy of dose. The prescribed dose to the PTV was 60 Gy in one fraction to the 80% isodose line, covering 95% of the delineated target with a Dmax of 75 Gy. Each arc used a photon energy of 6XFFF (flattening filter free), 1400 cGy/min dose rate, a 1 x 1 cm² collimator jaw setting, and the HD120 MLCs for "beams-eye" conformal shaping to the target volume. Using the anisotropic analytical algorithm (AAA), the resultant plan confirmed acceptable conformality for treating the TN patient.
MD-V3 Gafchromic film [13] was used for verification QA of the treatment plan. The extended dynamic dose range of this dosimetry media (1 to 100 Gy) and its high spatial resolution (down to 5 μm) makes it the ideal dosimeter to verify the absolute dose and distribution for such a small volume. A verification plan on a solid water phantom was created from the Eclipse treatment plan and sent to the TrueBeam STx for quality assurance measurements on the MD-V3 film. A separate set of dose calibration films were also acquired, and an H&D curve was obtained using calibrated ionization chamber measurements. The Gafchromic film was scanned on a flatbed scanner and analyzed using DoseLab software [14]. The results of the relative dose comparison showed that the measured isodose distribution was very close to the predicted (Figure 3).
FIGURE 3: Isodose Comparison

Comparison between measured (dashed) and calculated (solid) isodose lines. (Note: contours at edges were from marker used for isocenter localization.)

The gamma factor, using 3% dose and 1.0 mm distance to agreement (DTA), averaged a 99.5% pass rate over four separate repeat measurements. The gamma values showed excellent results (Figure 4).
Even though the measured relative isodose distribution was well-predicted by the treatment planning software, the absolute dose was measured at between 7-9% less than the calculated values. Since the MLCs were not used for dose modulation in a dynamic arc treatment (the plan was not VMAT), a multiplicative factor could be used to correct the plan monitor units (MUs) and thus, the final dose delivered. The measured absolute dose was improved to ±2 % of the calculated absolute dose by increasing the plan MUs by 7.5%. The resultant measured isodose distribution confirmed the same good agreement with the original plan isodose distribution. The gamma factor still exceeded a 99% pass rate.

After acceptable dose quality assurance was obtained, the focus was switched to accurate patient setup and immobilization. The aquaplast mask was cut out around the forehead, eyes, and nose area so that the patient could be monitored during treatment with the AlignRT [15] surface rendering module (Figure 5). This real time 3D system uses cameras and infra-red light to monitor the patient’s skin surface with sub-millimeter accuracy [16-19].
Initially, the patient was set up with the AlignRT reference surface from the body structure reconstructed from the simulation CT dataset. A cone beam CT (CBCT) was acquired, and the necessary table shifts were made. If any of the rotational shifts were greater than 1.5°, the patient’s head was gently rotated and the CBCT was repeated. After the appropriate isocenter was obtained, a new reference surface was acquired and monitored during the treatment. The patient’s isocenter maintained a vector accuracy of 1 mm during the entire treatment.

**Clinical results**

The patient was clinically evaluated at two weeks and three months following treatment. Her trigeminal pain was 80% resolved after two weeks, and 100% at the three-month evaluation. She was completely titrated off of all of her pre-treatment medications. She experienced no treatment-related sequelae. Specifically, the sensory function of all three trigeminal divisions was subjectively, and upon clinical testing, without deficit.

**Discussion**

This treatment utilized a new, modern image-guided linear accelerator with high-definition MLC’s to replace cone-based SRS delivery. Furthermore, CBCT and real-time surface monitoring was used instead of a frame-based system. The equipment for this technique is becoming more and more prevalent in community-based radiation oncology clinics.

The method utilized for treating our patient was relatively conventional, except for the treatment planning and the even more critical absolute dosimetry measurements. Since plans can be varied dramatically with respect to the number, length, and placement of arcs, the first two of these parameters were determined primarily by minimizing their interception with any organs at risk (OAR). The total number of arcs was dictated by the MU/degree capabilities of the linear accelerator and the need to maintain any normal tissue to a low integral dose.

We concluded that a standardized immobilization position during the simulation process would help alleviate the necessity to recreate completely different arc series for each new patient. Dynamic arcs were chosen as the delivery technique over static IMRT fields or RapidArc (VMAT) for a number of reasons. The total number of static fields needed to obtain an acceptable plan would be time-prohibitive (CyberKnife plans are typically 80-120 beam angles) and would substantially increase the total delivery time on a gantry-based linac system (gantry/couch rotation). As stated earlier, VMAT was not used because the small beamlets produced by the MLC modulation would add more uncertainty to the accuracy of the dose. Also, the absolute dose could not be adjusted accurately by simply multiplying the MUs from a VMAT plan as with a dynamic arc plan. The total treatment time was about one hour (CBCT setup time of 45 min and 12-13 minutes of beam-on time).

Even though the results are preliminary, they are very encouraging. We believe that the advent of this technique will provide a useful treatment option for radiation oncologists who have access to the equipment types that have been described in this paper. Our team spent countless hours perfecting this technique prior to its execution, and it is our hope that other professionals will be encouraged to consider our method as a treatment option when absolute dose can be confidently confirmed prior to treatment.

**Conclusions**

The TrueBeam STx linear accelerator with HD120 MLC’s, combined with the AlignRT
intrafraction motion management system and CBCT image guidance, offers an acceptable alternative for the radiation treatment of TN patients when compared to frame-based linear accelerator and Co-60 systems. The HD 120 MLC’s can accurately replace cones for the necessary enhanced collimation when the absolute doses have been measured prior to treatment. The end-to-end quality assurance measurements provided the confidence needed to safely and accurately deliver high dose to the trigeminal nerve [20].

Further immobilization, treatment planning (i.e. number of arcs, angles and arc degrees), and absolute dose verification techniques should be explored and reported.

**Additional Information**

**Disclosures**

**Human subjects:** Consent was obtained by all participants in this study.

**References**
